Tesla: Recovering Car Sales, Plus Non-Car Catalysts To Drive The Stock (Upgrade)

Tesla is down about 15% year to date, but the article argues the stock offers a Buy setup on recovering Model 3/Y sales, especially in Europe, and improving gross margins. The thesis also highlights more than $25B in 2026 capex aimed at unlocking factory capacity for Cybercab and Optimus, reinforcing Tesla's longer-term growth beyond autos. The piece is constructive on Tesla's profitability and strategic expansion, though it is opinion-based rather than a new company announcement.

Analysis

TSLA’s setup is less about the next quarter and more about whether investors start paying for the next platform cycle. If the core auto business is stabilizing while factory utilization improves, operating leverage can re-rate the stock before any true autonomy/robotics revenue exists; the market usually front-runs capex that converts idle capacity into a credible option value on new products. That makes the stock sensitive to delivery inflections and margin commentary over the next 1-2 quarters, but the bigger draw is whether management can keep dilution of the “car company multiple” narrative contained through 2025.

The second-order winner is likely the supply chain attached to incremental volume and factory expansion: battery materials, power electronics, and automation vendors should see better order visibility if capacity is unlocked for new form factors. The losers are legacy OEMs and EV pure plays that were hoping TSLA’s pricing pressure would remain elevated; a stabilization in Tesla’s margins implies the industry is no longer getting the same deflationary shock from aggressive discounting, which can lift ASPs across the segment and compress the relative valuation gap for better-capitalized competitors.

The main risk is timing mismatch: the equity may be pricing in 2026 catalysts that are still too far away to defend if near-term demand softens or macro hits auto affordability. A weaker Europe recovery or renewed price cuts would quickly turn the thesis from margin expansion to share defense, and the market will punish any sign that capex is consuming cash before producing visible volume. The contrarian read is that the move may be underdone if investors are still treating the stock as a single-line automaker, because the market often re-rates before ancillary businesses are monetized once capacity and narrative align.

Key Decisions for Investors

• Go long TSLA via 3-6 month call spreads, striking for a post-earnings rerate rather than a full autonomy story; target a 2:1 payoff if gross margin stability translates into upward estimate revisions.
• Add TSLA on weakness only after delivery/margin confirmation, not ahead of it; use a 2-4 week staggered entry to avoid paying for 2026 optionality too early.
• Pair long TSLA vs short a basket of legacy OEMs with higher ICE exposure if Europe demand is improving; thesis is relative margin and narrative expansion over the next 2-3 quarters.
• For risk control, cap exposure with protective puts around known delivery and earnings windows; if auto pricing re-accelerates downward, the thesis can de-rate within days even if the long-term story remains intact.